Search company, investor...

Compare Marillion Pharmaceuticals vs NanoMedex Pharmaceuticals

Customers evaluate the quality of Marillion Pharmaceuticals's products using the following success metrics.

Overview

Marillion Pharmaceuticals is 19 yrs old and is based in United States.

Marillion Pharmaceuticals, Inc. - Marillion is developing clinical-stage drugs in oncology and oncology supportive care. 177Lu-AMBA is a targeted radiotherapeutic, with the low level radiation of lutetium that aims to utilize an receptor-based technology, and can serve as both a diagnostic and therapeutic agent. The targeting capability means that 177Lu-AMBA homes in on tumor cells and spares normal tissues. 177Lu-AMBA is being pursued initially to treat hormone-resistant prostate cancer, has been studied in a phase I trial in Europe. Marillion also is developing PilobucTM , buccal formulation of pilocarpine ,for the treatment of dry mouth, shown in clinical trials to effectively and conveniently deliver the drug with reduced side effects compared to other routes of administration.PilobucTM buccal formulation of pilocarpine has the potential to be a product in the xerostomia market. Marillion is preparing for phase II trials of the product candidate..

NanoMedex Pharmaceuticals

NanoMedex uses patented formulation strategies to dissolve drugs in water that are only soluble in fats or lipids. Once dissolved in water, these drugs can be administrated intravenously. In hospitals, intravenous administration is preferred by older patients to eliminate swallowing, by physicians to increase certainty that the correct drug dose is given, and by health care providers to ensure that Medicare reimburses 100 percent of costs (versus 50 percent for oral administration).

Founded Year

Marillion Pharmaceuticals

2005